References
- United Nations Office of Drugs and Crime (UNODC). 2020. Executive Summary WDR20_BOOKLET_1.pdf (unodc.org)
- Ferland JN, Hurd YL. Deconstructing the neurobiology of cannabis use disorder. Nat Neurosci. 2020;23(5):600–10. doi:https://doi.org/10.1038/s41593-020-0611-0.
- Leung J, Chan GCK, Hides L, Hall WD. What is the prevalence and risk of cannabis use disorders among people who use cannabis? A systematic review and meta-analysis. Addict Behav. 2020;109:106479. doi:https://doi.org/10.1016/j.addbeh.2020.106479.
- Murray RM, Quigley H, Quattrone D, Englund A, Di Forti M. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry. 2016;15(3):195–204. doi:https://doi.org/10.1002/wps.20341.
- Volkow ND, Baler RD, Compton WM, Weiss SR. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219–27. doi:https://doi.org/10.1056/NEJMra1402309.
- Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017;8:9–37. doi:https://doi.org/10.2147/SAR.S109576.
- Bahji A, Stephenson C, Tyo R, Hawken ER, Seitz DP. Prevalence of Cannabis withdrawal symptoms among people with regular or dependent use of Cannabinoids: A systematic review and meta-analysis. JAMA Netw Open. 2020;3(4):e202370. doi:https://doi.org/10.1001/jamanetworkopen.2020.2370.
- Hasan A, von Keller R, Friemel CM, Hall W, Schneider M, Koethe D, Leweke FM, Strube W, Hoch E. Cannabis use and psychosis: a review of reviews. Eur Arch Psychiatry Clin Neurosci. 2020;270(4):403–12. doi:https://doi.org/10.1007/s00406-019-01068-z.
- Gage SH. Cannabis and psychosis: triangulating the evidence. Lancet Psychiatry. 2019;6(5):364–5. doi:https://doi.org/10.1016/S2215-0366(19)30086-0.
- Colizzi M, Weltens N, McGuire P, Lythgoe D, Williams S, Van Oudenhove L, Bhattacharyya S. Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis. Mol Psychiatry. 2020;25(12):3231–40. doi:https://doi.org/10.1038/s41380-019-0374-8.
- APA (American Psychiatric Association). Diagnostic and statistical manual of mental disorders (DSM-5). 5th ed. Washington, DC: American Psychiatric Association; 2013.
- European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Trendspotter briefing: impact of COVID-19 on patterns of drug use and drug-related harms in Europe June. 2020. EMCDDA-Trendspotter-Covid-19-Wave-2_1.pdf (europa.eu).
- Zaami S, Marinelli E, Varì MR. New trends of substance abuse during COVID-19 pandemic: an international perspective. Front Psychiatry. 2020; 11:700. doi:https://doi.org/10.3389/fpsyt.2020.00700.
- Riley DS, Barber MS, Kienle GS, Aronson JK, von Schoen-Angerer T, Tugwell P, Kiene H, Helfand M, Altman DG, Sox H, et al. CARE guidelines for case reports: explanation and elaboration document. J Clin Epidemiol. 2017;89:218–35. doi:https://doi.org/10.1016/j.jclinepi.2017.04.026.
- Casajuana Kögel C, Balcells-Olivero MM, López-Pelayo H, Miquel L, Teixidó L, Colom J, Nutt DJ, Rehm J, Gual A. The standard joint unit. Drug Alcohol Depend. 2017;176:109–16. doi:https://doi.org/10.1016/j.drugalcdep.2017.03.010.
- Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports. 1962;10(3):799–812. doi:https://doi.org/10.2466/pr0.1962.10.3.799
- Goodwin RS, Darwin WD, Chiang CN, Shih M, Li S-H, Huestis MA. Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol. 2008;32(8):562–6. doi:https://doi.org/10.1093/jat/32.8.562.
- Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiatry. 2012;7(4):149–56.
- Livne O, Shmulewitz D, Lev-Ran S, Hasin DS. DSM-5 cannabis withdrawal syndrome: demographic and clinical correlates in U.S. adults. Drug Alcohol Depend. 2019;195:170–7. doi:https://doi.org/10.1016/j.drugalcdep.2018.09.005.
- Valdés-Florido MJ, López-Díaz Á, Palermo-Zeballos FJ, Martínez-Molina I, Martín-Gil VE, Crespo-Facorro B, Ruiz-Veguilla M. Reactive psychoses in the context of the COVID-19 pandemic: Clinical perspectives from a case series. Rev. Psiquiatr. Salud Ment. 2020;13:90–94. doi:https://doi.org/10.1016/j.rpsm.2020.04.009.
- D’Agostino A, D’Angelo S, Giordano B, Cigognini AC, Chirico ML, Redaelli C, Gambini O. Brief Psychotic Disorder during the national lockdown in Italy: an emerging clinical phenomenon of the coronavirus pandemic. Schizophr Bull. 2020;47:15–22. doi:https://doi.org/10.1093/schbul/sbaa112.
- Brown E, Gray R, Lo Monaco S, O'Donoghue B, Nelson B, Thompson A, Francey S, McGorry P. The potential impact of COVID-19 on psychosis: A rapid review of contemporary epidemic and pandemic research. Schizophr Res. 2020;222:79–87. doi:https://doi.org/10.1016/j.schres.2020.05.005.
- Taylor S, Paluszek MM, Rachor GS, McKay D, Asmundson GJG. Substance use and abuse, COVID-19-related distress, and disregard for social distancing: A network analysis. Addict Behav. 2021;114:106754. doi:https://doi.org/10.1016/j.addbeh.2020.106754.
- Caudron M, Rolland B, Deheul S, Geoffroy PA, Thomas P, Amad A. Catatonia and cannabis withdrawal: a case report. Subst Abus. 2016;37(1):188–9. doi:https://doi.org/10.1080/08897077.2015.1052869.